UA100372C2 - Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины - Google Patents

Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины

Info

Publication number
UA100372C2
UA100372C2 UAA200909469A UAA200909469A UA100372C2 UA 100372 C2 UA100372 C2 UA 100372C2 UA A200909469 A UAA200909469 A UA A200909469A UA A200909469 A UAA200909469 A UA A200909469A UA 100372 C2 UA100372 C2 UA 100372C2
Authority
UA
Ukraine
Prior art keywords
cells
vaccine
isolated
peptid
application
Prior art date
Application number
UAA200909469A
Other languages
English (en)
Ukrainian (uk)
Inventor
Такуя Цунода
Рюдзі Охсава
Original Assignee
Онкотерапі Саєнс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапі Саєнс, Інк. filed Critical Онкотерапі Саєнс, Інк.
Publication of UA100372C2 publication Critical patent/UA100372C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Изобретение относится к выделенному пептиду, способному индуцировать цитотоксические Т-клетки, фармацевтической композиции, которая его содержит, эксзосоме, которая экспрессирует на своей поверхности комплекс, включающий данный пептид, способу индуцирования антигенпрезентирующей клетки. Изобретение также относится к способу индуцирования цитотоксичных Т-клеток, вакцине для ингибирования пролиферации клеток, способу скрининга пептида и т.п.
UAA200909469A 2007-02-21 2008-02-21 Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины UA100372C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
UA100372C2 true UA100372C2 (ru) 2012-12-25

Family

ID=39709837

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909469A UA100372C2 (ru) 2007-02-21 2008-02-21 Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины

Country Status (27)

Country Link
EP (20) EP2570430A3 (ru)
JP (6) JP5239103B2 (ru)
KR (8) KR101511140B1 (ru)
CN (4) CN103351423B (ru)
AR (1) AR068302A1 (ru)
AU (1) AU2008218463B2 (ru)
BR (1) BRPI0808421B1 (ru)
CA (3) CA2992074C (ru)
CO (1) CO6190536A2 (ru)
CY (2) CY1114590T1 (ru)
DK (3) DK2121731T3 (ru)
ES (6) ES2540893T3 (ru)
HR (3) HRP20131044T1 (ru)
IL (10) IL200478A (ru)
MX (4) MX359680B (ru)
MY (2) MY173379A (ru)
NZ (4) NZ579768A (ru)
PH (1) PH12014501642A1 (ru)
PL (3) PL2476694T3 (ru)
PT (2) PT2465864E (ru)
RU (1) RU2464275C2 (ru)
SG (3) SG10201909675QA (ru)
SI (3) SI2121731T1 (ru)
TW (5) TWI615403B (ru)
UA (1) UA100372C2 (ru)
WO (1) WO2008102557A1 (ru)
ZA (1) ZA200905881B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882698B (zh) 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
US8455444B2 (en) * 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
WO2010001585A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2362906B1 (en) * 2008-10-22 2015-04-08 Oncotherapy Science, Inc. Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
KR20110117112A (ko) * 2008-12-24 2011-10-26 온코세라피 사이언스 가부시키가이샤 Ｃ１ｏｒｆ５９ 펩티드 및 이를 포함하는 백신
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
ES2575160T3 (es) * 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
TW201627003A (zh) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
WO2012073459A1 (en) * 2010-12-02 2012-06-07 Oncotherapy Science, Inc. Tomm34 peptides and vaccines including the same
ES2746058T3 (es) 2011-12-14 2020-03-04 Univ Texas Biomarcadores colaterales de inactivación génica y dianas para el tratamiento del cáncer
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
US9644010B2 (en) * 2012-07-10 2017-05-09 Oncotherapy Science, Inc. LY6K epitope peptides for TH1 cells and vaccines containing the same
US9561265B2 (en) 2012-07-10 2017-02-07 Oncotherapy Science, Inc. KIF20A epitope peptides for TH1 cells and vaccines containing the same
NO2891663T3 (ru) * 2012-08-31 2018-05-19
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR20160029127A (ko) * 2013-07-12 2016-03-14 다이니뽄 스미토모 세이야쿠 가부시키가이샤 종양 항원 펩티드
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
RU2700881C2 (ru) 2014-08-04 2019-09-23 Онкотерапи Сайенс, Инк. Пептид, полученный из urlc10, и содержащая его вакцина
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
CR20180519A (es) * 2016-03-31 2019-03-05 Neon Therapeutics Inc Neoantígenos y métodos de su uso
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
KR102148866B1 (ko) * 2017-08-10 2020-10-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
KR102267463B1 (ko) * 2018-02-15 2021-06-21 코쿠리츠다이가쿠호진 아사히카와 이카다이가쿠 암 항원 펩티드
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) * 2019-12-31 2021-07-16 上海细胞治疗集团有限公司 一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
AU702522B2 (en) * 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100631766B1 (ko) * 1997-10-07 2006-10-09 오노 야꾸힝 고교 가부시키가이샤 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및그들의 용도
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) * 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2478063A1 (en) * 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1572736A2 (en) * 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
EP1572118A4 (en) * 2002-12-20 2010-07-14 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1882698B (zh) * 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
JP2007525203A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４
JP4761389B2 (ja) * 2004-04-09 2011-08-31 株式会社ジーンケア研究所 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
MX2007010349A (es) * 2005-02-24 2008-04-09 Cemines Inc Composiciones y metodos para clasificar muestras biologicas.
PL2325306T3 (pl) * 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
US8030443B2 (en) * 2005-08-09 2011-10-04 Kurume University Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule
ES2373055T3 (es) * 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US20090263832A1 (en) * 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
CN103351425B (zh) * 2006-04-10 2016-01-20 健泰科生物技术公司 散乱蛋白pdz调节剂
CN105418751B (zh) * 2006-06-16 2019-03-05 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US8455444B2 (en) * 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2483690A1 (de) * 2009-09-29 2012-08-08 Protagen AG Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
JP5874158B2 (ja) 2016-03-02
KR20130023407A (ko) 2013-03-07
HK1172346A1 (en) 2013-04-19
MX337456B (es) 2016-03-03
ZA200905881B (en) 2010-05-26
HRP20131044T1 (hr) 2013-12-06
EP2465867B1 (en) 2015-04-01
AR068302A1 (es) 2009-11-11
JP2010209060A (ja) 2010-09-24
JP2016094459A (ja) 2016-05-26
EP2121731A4 (en) 2010-04-21
IL219042A0 (en) 2012-05-31
KR20160045939A (ko) 2016-04-27
HK1172345A1 (en) 2013-04-19
HK1172344A1 (en) 2013-04-19
EP2476693A3 (en) 2012-10-03
EP2567971A2 (en) 2013-03-13
CA2678755C (en) 2016-04-26
EP2565203A1 (en) 2013-03-06
KR101644877B1 (ko) 2016-08-03
KR20150064236A (ko) 2015-06-10
CA2919248A1 (en) 2008-08-28
EP2476692A3 (en) 2012-12-19
ES2527397T3 (es) 2015-01-23
EP2476693B1 (en) 2014-12-24
EP2573110A2 (en) 2013-03-27
CA2992074C (en) 2021-01-05
IL219048A0 (en) 2012-05-31
JP5239104B2 (ja) 2013-07-17
CN103351423A (zh) 2013-10-16
IL200478A0 (en) 2010-04-29
EP2465864A2 (en) 2012-06-20
HK1172042A1 (en) 2013-04-12
BRPI0808421B1 (pt) 2021-10-05
CO6190536A2 (es) 2010-08-19
JP2013116895A (ja) 2013-06-13
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
AU2008218463B2 (en) 2013-01-17
CY1115841T1 (el) 2017-01-25
IL219044A (en) 2014-12-31
JP5608953B2 (ja) 2014-10-22
EP2570428A2 (en) 2013-03-20
DK2465864T3 (en) 2014-11-24
EP2476693A2 (en) 2012-07-18
PT2121731E (pt) 2013-10-24
CN101663315B (zh) 2014-10-15
JP2010519176A (ja) 2010-06-03
EP2121731B1 (en) 2013-08-14
EP2465865B1 (en) 2016-11-02
IL219043A0 (en) 2012-05-31
BRPI0808421A2 (pt) 2017-08-29
EP2465864B1 (en) 2014-10-08
CN104292299B (zh) 2017-09-29
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
IL219048A (en) 2015-07-30
EP2594582A3 (en) 2013-08-14
KR101540000B1 (ko) 2015-07-29
IL219045A0 (en) 2012-05-31
TWI438207B (zh) 2014-05-21
KR101511140B1 (ko) 2015-04-10
MY173379A (en) 2020-01-21
EP2465864A3 (en) 2012-10-03
EP2574623A2 (en) 2013-04-03
DK2121731T3 (da) 2013-10-21
PL2121731T3 (pl) 2014-01-31
IL219041A0 (en) 2012-05-31
EP2476694A2 (en) 2012-07-18
TW201422637A (zh) 2014-06-16
KR101644871B1 (ko) 2016-08-02
RU2464275C2 (ru) 2012-10-20
PH12014501642B1 (en) 2015-12-02
EP2594582A2 (en) 2013-05-22
KR20090121349A (ko) 2009-11-25
KR101543623B1 (ko) 2015-08-11
CN104292299A (zh) 2015-01-21
CA2992074A1 (en) 2008-08-28
ES2532708T3 (es) 2015-03-31
KR20150116463A (ko) 2015-10-15
SI2476694T1 (sl) 2015-02-27
PL2476694T3 (pl) 2015-04-30
NZ602122A (en) 2014-03-28
EP2573109A2 (en) 2013-03-27
EP2570429A3 (en) 2013-08-28
EP2465867A2 (en) 2012-06-20
EP2570430A3 (en) 2013-07-10
EP2465866A3 (en) 2012-10-10
EP2567971A3 (en) 2013-06-26
KR101511134B1 (ko) 2015-04-28
CN101663315A (zh) 2010-03-03
EP2570429A2 (en) 2013-03-20
PT2465864E (pt) 2015-01-14
EP2465867A3 (en) 2012-10-10
IL219040A0 (en) 2012-05-31
NZ591704A (en) 2012-09-28
WO2008102557A1 (en) 2008-08-28
KR20150018895A (ko) 2015-02-24
ES2540893T3 (es) 2015-07-14
EP2465865A3 (en) 2013-07-24
MX359680B (es) 2018-09-28
EP2476694A3 (en) 2013-04-24
JP2014210804A (ja) 2014-11-13
ES2530777T3 (es) 2015-03-05
HK1134507A1 (en) 2010-04-30
RU2009135020A (ru) 2011-03-27
NZ602119A (en) 2014-03-28
AU2008218463A1 (en) 2008-08-28
TWI615403B (zh) 2018-02-21
JP5614761B2 (ja) 2014-10-29
CY1114590T1 (el) 2016-10-05
JP5239103B2 (ja) 2013-07-17
EP2573109A3 (en) 2013-06-19
IL219043A (en) 2014-12-31
NZ579768A (en) 2012-03-30
EP2121731A1 (en) 2009-11-25
SG179402A1 (en) 2012-04-27
EP2476692B1 (en) 2015-04-15
HRP20150108T1 (hr) 2015-05-08
CN103351423B (zh) 2016-09-28
TWI596109B (zh) 2017-08-21
IL200478A (en) 2015-11-30
ES2435194T3 (es) 2013-12-16
EP2476692A2 (en) 2012-07-18
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
IL219046A (en) 2015-02-26
TWI610939B (zh) 2018-01-11
EP2476695A3 (en) 2012-12-12
SI2465864T1 (sl) 2014-12-31
DK2476694T3 (en) 2014-12-08
IL219041A (en) 2014-12-31
EP2465865A2 (en) 2012-06-20
EP2583976A3 (en) 2013-10-23
EP2573110A3 (en) 2013-09-04
EP2594581A2 (en) 2013-05-22
SG10201909675QA (en) 2019-11-28
TW201538522A (zh) 2015-10-16
EP2594581A3 (en) 2013-08-14
MX337417B (es) 2016-03-03
EP2465866A2 (en) 2012-06-20
IL219040A (en) 2014-12-31
HRP20141233T1 (hr) 2015-02-27
EP2583976A2 (en) 2013-04-24
EP2570430A2 (en) 2013-03-20
ES2541863T3 (es) 2015-07-27
SI2121731T1 (sl) 2013-10-30
PL2465864T3 (pl) 2015-03-31
TWI494319B (zh) 2015-08-01
HK1172041A1 (en) 2013-04-12
IL219047A0 (en) 2012-05-31
MY155029A (en) 2015-08-28
TW201623325A (zh) 2016-07-01
EP2574623A3 (en) 2013-07-17
TW200844111A (en) 2008-11-16
EP2476694B1 (en) 2014-11-19
KR20140121489A (ko) 2014-10-15
HK1172043A1 (en) 2013-04-12
IL219042A (en) 2016-03-31
KR20140130507A (ko) 2014-11-10
IL219044A0 (en) 2012-05-31
EP2476695A2 (en) 2012-07-18
TW201433574A (zh) 2014-09-01
JP2013091645A (ja) 2013-05-16
MX2009009022A (es) 2010-03-03
PH12014501642A1 (en) 2015-12-02
SG10201506589WA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
CY1119366T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CY1119744T1 (el) Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
EA201792632A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
MX2020012775A (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer.
EA201000208A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
CY1115999T1 (el) Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη
CR20200594A (es) NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
EA201891116A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака
EA201890635A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии мелкоклеточного рака легких и других видов рака
EA201890027A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии эпителиального рака яичника и других видов рака
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
MX2019005272A (es) Peptidos cancerigenos universales derivados de telomerasa.
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
EA201891638A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201791853A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
BR112012011332A2 (pt) agentes direcionados para gadd45beta
EA201890440A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака предстательной железы и других видов рака
EA201891701A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии немелкоклеточного рака легких и других видов рака
WO2011143656A3 (en) Compositions and methods of identifying tumor specific neoantigens
EA201792671A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака пищевода и других видов рака
BRPI0808421A2 (pt) Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula.
EA201892333A1 (ru) Иммунотерапия меланомы и других видов рака
EA201892159A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака